Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Enoxaparin (Lovenox) and Savaysa (edoxaban) are both blood thinners used to prevent and treat blood clots, but they have some key differences. Enoxaparin is an injectable medication, while Savaysa is taken orally. Enoxaparin is available in both brand and generic forms, whereas Savaysa is currently only available as a brand-name medication. Enoxaparin is often used during pregnancy, except for those with prosthetic heart valves. However, Savaysa isn’t recommended during pregnancy due to limited safety data. Neither medication requires blood test monitoring. Both can cause bleeding, but only enoxaparin has an antidote to reverse serious bleeding. Additionally, enoxaparin dose is based on weight and specific conditions, while Savaysa has a standard dose of 60 mg once daily.
Enoxaparin (Lovenox)
Savaysa (edoxaban)
Enoxaparin (Lovenox)
Savaysa (edoxaban)
Summary of Lovenox vs. Savaysa
Summary for Anticoagulant
Prescription only
Enoxaparin (Lovenox) is a blood thinner that's used to treat and prevent blood clots and other clotting-related conditions. It's given as an injection under the skin in the stomach. The dosing for enoxaparin (Lovenox) depends mostly on your weight, but also on why you need the medication. Enoxaparin (Lovenox) is a preferred choice for pregnant women, but it might not be the best option if they have prosthetic (artificial) heart valves. Side effects aren't common, but can include bleeding or bruising at the injection site. Enoxaparin (Lovenox) is available as a brand and generic medication.
Summary for Anticoagulant
Prescription only
Savaysa, the brand name for edoxaban, is an anticoagulant (blood thinner). It’s used to help prevent blood clots and strokes in certain people with atrial fibrillation. This medication can also treat blood clots. The dose is typically one 60 mg tablet by mouth once daily, but it might be lower if you have kidney problems. Since it’s a blood thinner medication, Savaysa (edoxaban) can raise your chance of bleeding as a side effect. As of early 2025, there's no FDA-approved generic version available yet.